A detailed history of Marshall Wace, LLP transactions in Annexon, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 292,374 shares of ANNX stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
292,374
Previous 1,693,665 82.74%
Holding current value
$1.51 Million
Previous $8.3 Million 79.15%
% of portfolio
0.0%
Previous 0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.49 - $7.2 $6.29 Million - $10.1 Million
-1,401,291 Reduced 82.74%
292,374 $1.73 Million
Q2 2024

Aug 14, 2024

BUY
$4.33 - $6.79 $5.97 Million - $9.36 Million
1,378,053 Added 436.63%
1,693,665 $8.3 Million
Q1 2024

May 15, 2024

BUY
$4.03 - $7.81 $1.27 Million - $2.46 Million
315,612 New
315,612 $2.26 Million
Q1 2023

May 15, 2023

BUY
$3.74 - $7.46 $1.63 Million - $3.25 Million
435,963 Added 1510.82%
464,819 $1.79 Million
Q4 2022

Feb 14, 2023

BUY
$4.56 - $6.61 $131,583 - $190,738
28,856 New
28,856 $149,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $27,875 - $53,636
-13,211 Reduced 46.89%
14,961 $56,000
Q1 2022

May 16, 2022

BUY
$2.73 - $11.94 $59,819 - $261,629
21,912 Added 350.03%
28,172 $77,000
Q4 2021

Feb 14, 2022

BUY
$11.49 - $22.0 $71,927 - $137,720
6,260 New
6,260 $73,000

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $246M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.